These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Patients with severe mental illness and hepatitis C virus infection benefit from new pangenotypic direct-acting antivirals: Results of a literature review. Gutiérrez-Rojas L; de la Gándara Martín JJ; García Buey L; Uriz Otano JI; Mena Á; Roncero C Gastroenterol Hepatol; 2023 May; 46(5):382-396. PubMed ID: 35718017 [TBL] [Abstract][Full Text] [Related]
6. Impact of direct-acting antivirals (DAAs) on cardiovascular diseases in patients with chronic hepatitis C. Pennisi G; Spatola F; DI Marco L; DI Martino V; DI Marco V Minerva Gastroenterol (Torino); 2021 Sep; 67(3):254-263. PubMed ID: 33971709 [TBL] [Abstract][Full Text] [Related]
7. Direct-acting antivirals in relapsed or refractory hepatitis C virus-associated diffuse large B-cell lymphoma. Merli M; Defrancesco I; Visco C; Besson C; Di Rocco A; Arcari A; Sica A; Cencini E; Tisi MC; Frigeni M; Grossi P; Bianchi B; Mora B; Bertù L; Bruno R; Passamonti F; Arcaini L Leuk Lymphoma; 2020 Sep; 61(9):2122-2128. PubMed ID: 32343165 [TBL] [Abstract][Full Text] [Related]
8. Cardiovascular Manifestations of Hepatitis C Virus. Goossens N; Negro F Clin Liver Dis; 2017 Aug; 21(3):465-473. PubMed ID: 28689586 [TBL] [Abstract][Full Text] [Related]
9. High rate of sustained virological response with direct-acting antivirals in haemophiliacs with HCV infection: A multicenter study. Mancuso ME; Linari S; Santagostino E; Bartolozzi D; D'Ambrosio R; Borghi M; Lampertico P; Peyvandi F; Castaman G; Aghemo A Liver Int; 2020 May; 40(5):1062-1068. PubMed ID: 31876354 [TBL] [Abstract][Full Text] [Related]
10. Sustained virological response to hepatitis C treatment decreases the incidence of complications associated with type 2 diabetes. Li J; Gordon SC; Rupp LB; Zhang T; Trudeau S; Holmberg SD; Moorman AC; Spradling PR; Teshale EH; Boscarino JA; Schmidt MA; Daida YG; Lu M; Aliment Pharmacol Ther; 2019 Mar; 49(5):599-608. PubMed ID: 30650468 [TBL] [Abstract][Full Text] [Related]
11. The clinical impact of direct-acting antiviral treatment on patients affected by hepatitis C virus-related oral lichen planus: a cohort study. Di Stasio D; Lucchese A; Romano A; Adinolfi LE; Serpico R; Marrone A Clin Oral Investig; 2022 Aug; 26(8):5409-5417. PubMed ID: 35477818 [TBL] [Abstract][Full Text] [Related]
12. Neuropsychological effects of direct-acting antiviral treatment for Hepatitis C virus subjects: A systematic review. Santos-Lima C; Souza-Marques B; Vieira F; Isabel Schinoni M; Quarantini LC; Abreu N J Viral Hepat; 2021 Dec; 28(12):1672-1682. PubMed ID: 34320255 [TBL] [Abstract][Full Text] [Related]
13. The risk of hepatitis C virus recurrence in hepatitis C virus-infected patients treated with direct-acting antivirals after achieving a sustained virological response: A comprehensive analysis. Huang P; Wang Y; Yue M; Ge Z; Xia X; Jeyarajan AJ; Holmes JA; Yu R; Zhu C; Yang S; Lin W; Chung RT Liver Int; 2021 Oct; 41(10):2341-2357. PubMed ID: 34051040 [TBL] [Abstract][Full Text] [Related]
14. Hepatocellular carcinoma after direct-acting antiviral hepatitis C virus therapy: A debate near the end. Muzica CM; Stanciu C; Huiban L; Singeap AM; Sfarti C; Zenovia S; Cojocariu C; Trifan A World J Gastroenterol; 2020 Nov; 26(43):6770-6781. PubMed ID: 33268960 [TBL] [Abstract][Full Text] [Related]
15. Direct-Acting Antivirals in Hepatitis C Virus-Associated Diffuse Large B-cell Lymphomas. Merli M; Frigeni M; Alric L; Visco C; Besson C; Mannelli L; Di Rocco A; Ferrari A; Farina L; Pirisi M; Piazza F; Loustaud-Ratti V; Arcari A; Marino D; Sica A; Goldaniga M; Rusconi C; Gentile M; Cencini E; Benanti F; Rumi MG; Ferretti VV; Grossi P; Gotti M; Sciarra R; Tisi MC; Cano I; Zuccaro V; Passamonti F; Arcaini L Oncologist; 2019 Aug; 24(8):e720-e729. PubMed ID: 30552159 [TBL] [Abstract][Full Text] [Related]
16. Antiviral treatment does not improve subclinical atheromatosis in patients with chronic hepatitis caused by hepatitis C virus. Revuelto Artigas T; Betriu Bars À; Zaragoza Velasco N; Gómez Arbones X; Vidal Ballester T; Piñol Felis C; Reñé Espinet JM Gastroenterol Hepatol; 2019; 42(6):362-371. PubMed ID: 30952463 [TBL] [Abstract][Full Text] [Related]
17. Hepatitis C virus eradication by direct-acting antiviral agents improves carotid atherosclerosis in patients with severe liver fibrosis. Petta S; Adinolfi LE; Fracanzani AL; Rini F; Caldarella R; Calvaruso V; Cammà C; Ciaccio M; Di Marco V; Grimaudo S; Licata A; Marrone A; Nevola R; Pipitone RM; Pinto A; Rinaldi L; Torres D; Tuttolomondo A; Valenti L; Fargion S; Craxì A J Hepatol; 2018 Jul; 69(1):18-24. PubMed ID: 29505844 [TBL] [Abstract][Full Text] [Related]
18. Sofosbuvir-based regimens for HCV in stage 4-stage 5 chronic kidney disease. A systematic review with meta-analysis. Fabrizi F; Cerutti R; Dixit V; Ridruejo E Nefrologia (Engl Ed); 2021; 41(5):578-589. PubMed ID: 36165141 [TBL] [Abstract][Full Text] [Related]
19. Extrahepatic manifestations of HCV: the role of direct acting antivirals. Polo ML; Laufer N Expert Rev Anti Infect Ther; 2017 Aug; 15(8):737-746. PubMed ID: 28696154 [TBL] [Abstract][Full Text] [Related]
20. Improved diabetes control, allowing insulin cessation, after direct acting antiviral treatment (DAAT) of hepatitis C. Surendran A; Bhalla A; Whyte MB BMJ Case Rep; 2022 Apr; 15(4):. PubMed ID: 35450872 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]